An Oral AR/AR-V7 PROTAC for the Treatment with Castration-Resistant Prostate Cancer (CRPC)
An oral bioavailable PROTAC drug targeting both AR and AR-V7 for the treatment of castration-resistant prostate cancer (CRPC) was developed by Industrial Technology Research Institute. This innovative drug effectively degrades AR and AR-V7 proteins within prostate cancer cells, resulting in the inhibition of castration-resistant tumor growth. The preclinical toxicology study has demonstrated the drug's favorable safety profile, highlighting its potential as a novel protein degradation drug. ITRI's oral bioavailable AR/AR-V7 PROTAC drug represents a significant advancement in the field of prostate cancer treatment and offers a promising therapeutic option for patients with CRPC.
Features & Specifications:
・Targeted protein degradation capability
・Superior effectiveness compared to approved drugs
・Low adverse effects and high safety
ITRI is a world-leading applied technology research institute with more than 6,000 outstanding employees. Its mission is to drive industrial development, create economic value, and enhance social well-being through technology R&D. Founded in 1973, it pioneered in IC development and started to nurture new tech ventures and deliver its R&D results to industries. ITRI has set up and incubated companies such as TSMC, UMC, Taiwan Mask Corp., Epistar Corp., Mirle Automation Corp., and Taiwan Biomaterial Co.
Name:Juno Chen
Phone:
Address:195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, Taiwan 31040, R.O.C.
A deep learning-powered novel artificial intelligence algorithm and syste m to assist in the identification of pneumoperitoneum on abdominal com puted tomography
Administration with recombinant fragment of human SP-D (rfhSP-D) in t he diagnosis and treatment for chronic obstructive pulmonary disease
A Wearable and Self-powered Multifunctional Module for Active Infectio n Prevention, Accelerated Wound Healing and Noninvasive Healing Moni toring
One Model Fit All: Revolutionary One-Stop Shop System for Predicting Co ronary Stenosis without Normal Database in Myocardial Perfusion Imagin g
Technology maturity:Prototype
Exhibiting purpose:Technology transactions、Display of scientific results
Trading preferences:Technical license/cooperation
Coming soon!